Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

fludarabine 10Cyclophosphamide 8fludarabine phosphate 7Whole-Body Irradiation 7Tacrolimus 5Mycophenolic Acid 5Melphalan 5Thiotepa 4Peripheral Blood Stem Cell Transplantation 4Busulfan 4AP 1903 reagent 4thymoglobulin 3Sirolimus 3Cord Blood Stem Cell Transplantation 3Alemtuzumab 3Stem Cell Transplantation 2Specimen Handling 2Rituximab 2Platelet Transfusion 2Meropenem 2Cyclosporine 2Biopsy 2Antilymphocyte Serum 2visilizumab 1venetoclax 1trametinib 1ruxolitinib 1regorafenib 1ponatinib 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hematologic Neoplasms × Calcineurin Inhibitors × Classical hematology × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡